UCB’s BIMZELX® (bimekizumab-bkzx) has been approved by the FDA, representing a major milestone in the treatment of adults with moderate
The IPC is proud to announce a collaboration with the National Psoriasis Foundation (NPF) in unveiling new insights into the
The University of Oxford seeks 2000 psoriasis volunteers for a groundbreaking study exploring the link between the skin condition and
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira®
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib,
The United States Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) granted these designations based on
The European Commission has approved Sotyktu™ (deucravacitinib) in European Union.
Amgen receives approval from the United States Food and Drug Administration (FDA) for AMJEVITA™, a biosimilar for adults with psoriasis
This announcement follows the September 2022 approval from the U.S. Food and Drug Administration (FDA) and the Japan’s Ministry of
